LIF Antibody [Unconjugated]

LIF was detected in immersion fixed paraffin-embedded sections of human lung array using Goat Anti-Human LIF Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-250-NA) at 25 µg/mL overnight at 4 °C. Tissue was stained using the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; CTS008) and counterstained with hematoxylin (blue). Lower panel shows a lack of labeling if primary antibodies are omitted and tissue is stained only with secondary antibody followed by incubation with detection reagents. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.

LIF was detected in immersion fixed paraffin-embedded sections of human Alzheimer's brain using Goat Anti-Human LIF Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-250-NA) at 10 µg/mL overnight at 4 °C. Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using Antigen Retrieval Reagent-Basic CTS013). Tissue was stained using the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown CTS008) and counterstained with hematoxylin (blue). Specific staining was localized to neuronal cytoplasm. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.

Recombinant Human LIF (Catalog # 7734-LF) stimulates proliferation in the TF‑1 human erythroleukemic cell line in a dose-depend­ent manner (orange line), as measured by Resazurin (Catalog # AR002). Proliferation elicited by 3 ng/mL Recombinant Human LIF is neutralized (green line) by increasing concentrations of Goat Anti-Human LIF Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-250-NA). The ND50 is typically0.04‑0.08 µg/mL.

LIF promotes Glut1 PM translocation through the activation of AKT signaling.A LIF activated the AKT signaling, which can be blocked by MK2206, an AKT inhibitor (upper panel), or Wortmannin (Wort), a PI3K inhibitor (lower panel), in MCF7, MDA-MB 231 and T47D cells. The levels of p-AKTSer473 (p-AKT), which reflect the activity of AKT were measured by Western-blot assays. B Blocking AKT signaling by MK2206 (left) or Wortmannin (right) largely abolished the promoting effect of LIF on Glut1 PM translocation in breast cancer cells. C, D Blocking AKT signaling by expression of dominant-negative AKT (AKT-DN) largely abolished the promoting effect of LIF on Glut1 PM translocation in breast cancer cells. Cells were transfected with vectors expressing AKT-DN. The levels of p-AKT and total AKT (C), as well as Glut1 PM translocation (D), were determined by Western-blot assays. Uncropped Western-blot images are shown in Supplementary Fig 3. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/35440095), licensed under a CC-BY license. Not internally tested by R&D Systems.

LIF promotes Glut1 PM translocation through the activation of AKT signaling.A LIF activated the AKT signaling, which can be blocked by MK2206, an AKT inhibitor (upper panel), or Wortmannin (Wort), a PI3K inhibitor (lower panel), in MCF7, MDA-MB 231 and T47D cells. The levels of p-AKTSer473 (p-AKT), which reflect the activity of AKT were measured by Western-blot assays. B Blocking AKT signaling by MK2206 (left) or Wortmannin (right) largely abolished the promoting effect of LIF on Glut1 PM translocation in breast cancer cells. C, D Blocking AKT signaling by expression of dominant-negative AKT (AKT-DN) largely abolished the promoting effect of LIF on Glut1 PM translocation in breast cancer cells. Cells were transfected with vectors expressing AKT-DN. The levels of p-AKT and total AKT (C), as well as Glut1 PM translocation (D), were determined by Western-blot assays. Uncropped Western-blot images are shown in Supplementary Fig 3. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/35440095), licensed under a CC-BY license. Not internally tested by R&D Systems.

LIF promotes Glut1 PM translocation through the activation of AKT signaling.A LIF activated the AKT signaling, which can be blocked by MK2206, an AKT inhibitor (upper panel), or Wortmannin (Wort), a PI3K inhibitor (lower panel), in MCF7, MDA-MB 231 and T47D cells. The levels of p-AKTSer473 (p-AKT), which reflect the activity of AKT were measured by Western-blot assays. B Blocking AKT signaling by MK2206 (left) or Wortmannin (right) largely abolished the promoting effect of LIF on Glut1 PM translocation in breast cancer cells. C, D Blocking AKT signaling by expression of dominant-negative AKT (AKT-DN) largely abolished the promoting effect of LIF on Glut1 PM translocation in breast cancer cells. Cells were transfected with vectors expressing AKT-DN. The levels of p-AKT and total AKT (C), as well as Glut1 PM translocation (D), were determined by Western-blot assays. Uncropped Western-blot images are shown in Supplementary Fig 3. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/35440095), licensed under a CC-BY license. Not internally tested by R&D Systems.

LIF promotes Glut1 PM translocation through the activation of AKT signaling.A LIF activated the AKT signaling, which can be blocked by MK2206, an AKT inhibitor (upper panel), or Wortmannin (Wort), a PI3K inhibitor (lower panel), in MCF7, MDA-MB 231 and T47D cells. The levels of p-AKTSer473 (p-AKT), which reflect the activity of AKT were measured by Western-blot assays. B Blocking AKT signaling by MK2206 (left) or Wortmannin (right) largely abolished the promoting effect of LIF on Glut1 PM translocation in breast cancer cells. C, D Blocking AKT signaling by expression of dominant-negative AKT (AKT-DN) largely abolished the promoting effect of LIF on Glut1 PM translocation in breast cancer cells. Cells were transfected with vectors expressing AKT-DN. The levels of p-AKT and total AKT (C), as well as Glut1 PM translocation (D), were determined by Western-blot assays. Uncropped Western-blot images are shown in Supplementary Fig 3. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/35440095), licensed under a CC-BY license. Not internally tested by R&D Systems.

• Reactivity: Hu
• Applications: IHC, B/N
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Unconjugated
• Concentration: LYOPH

LIF Antibody [Unconjugated] Summary

• Immunogen: E. coli-derived recombinant human LIF
  Ser23-Phe202
  Accession # P15018
• Specificity: Detects human LIF in direct ELISAs.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Gene: LIF
• Purity Statement: Antigen Affinity-purified
• Endotoxin Note: <0.10 EU per 1 μg of the antibody by the LAL method.

Applications/Dilutions

• Dilutions:
  • Immunohistochemistry 5-15 ug/mL
  • Neutralization 0.04-0.08 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.2 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for LIF Antibody [Unconjugated]

• CDF
• D Factor
• DIA
• differentiation inhibitory activity
• differentiation stimulating factor
• Differentiation-stimulating factor
• Emfilermin
• HILDA
• HILDAcholinergic differentiation factor
• leukemia inhibitory factor (cholinergic differentiation factor)
• leukemia inhibitory factor
• LIF
• Melanoma-derived LPL inhibitor
• MLPLI

Background

LIF (Leukemia inhibitory factor; also  Differentiation-stimulating factor) is a 22 kDa (predicted) glycoprotein, member of  the leukemia inhibitory factor/interleukin-6 (LIF/IL-6) family of cytokines. Natural LIF is heavily glycosylated, showing an apparent molecular weight of 32 kDa to 62 kDa, it is produced by a variety of cells including T cells, monocytes, fibroblasts, osteoblasts and mast cells. LIF induces hematopoietic differentiation in normal and myeloid leukemia cells, neuronal cell differentiation and stimulation of acute-phase protein synthesis in hepatocytes. Human LIF acts through a receptor comprising a 190 kDa LIF-binding alpha -chain and a 130 kDa signal-transducing beta -chain (gp130), which is shared with the other members of the IL-6 family. Human and mouse LIF exhibit 78% aa sequence identity.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for LIF Antibody (AF-250-NA)(18)

Publications using AF-250-NA

• Ding, C;Hashimoto, N;Kano, F;Tenshin, H;Arai, T;Xia, L;Xu, Y;Lao, H;Wang, Y;Iwasaki, T;Hibi, H;Yamamoto, A; Factors secreted from the stem cells of human exfoliated deciduous teeth inhibit osteoclastogenesis through the activation of the endogenous antioxidant system Journal of oral biosciences 2025-01-22 [PMID: 39855425] (Neutralization, Human)
• X Yue, J Wang, CY Chang, J Liu, X Yang, F Zhou, X Qiu, V Bhatt, JY Guo, X Su, L Zhang, Z Feng, W Hu Leukemia inhibitory factor drives glucose metabolic reprogramming to promote breast tumorigenesis Cell Death & Disease, 2022-04-19;13(4):370. 2022-04-19 [PMID: 35440095] (Neutralization, Human)
• M Kessler, K Hoffmann, K Fritsche, V Brinkmann, HJ Mollenkopf, O Thieck, AR Teixeira d, EI Braicu, J Sehouli, M Mangler, H Berger, TF Meyer Chronic Chlamydia infection in human organoids increases stemness and promotes age-dependent CpG methylation Nat Commun, 2019-03-18;10(1):1194. 2019-03-18 [PMID: 30886143] (Neutralization, Human)
• K McLean, L Tan, DE Bolland, LG Coffman, LF Peterson, M Talpaz, N Neamati, RJ Buckanovic Leukemia inhibitory factor functions in parallel with interleukin-6 to promote ovarian cancer growth Oncogene, 2018-10-10;0(0):. 10/10/2018 [PMID: 30305729]
• JE Yoon, Y Kim, S Kwon, M Kim, YH Kim, JH Kim, TJ Park, HY Kang Senescent fibroblasts drive ageing pigmentation: ?A potential therapeutic target for senile lentigo Theranostics, 2018-09-09;8(17):4620-4632. 2018-09-09 [PMID: 30279727] (IHC-P, Human)
• F Wu, X Chen, Y Liu, B Liang, H Xu, TC Li, CC Wang Decreased MUC1 in endometrium is an independent receptivity marker in recurrent implantation failure during implantation window Reprod. Biol. Endocrinol., 2018-06-21;16(1):60. 2018-06-21 [PMID: 29929546] (IHC, Human)
• C Ueshima, TR Kataoka, M Hirata, A Sugimoto, Y Iemura, S Minamiguch, T Nomura, H Haga Possible involvement of human mast cells in the establishment of pregnancy via KIR2DL4 Am. J. Pathol., 2018-03-22;0(0):. 2018-03-22 [PMID: 29577936] (Neutralization, Human)
• Amy Winship, Jeanne Correia, Jian-Guo Zhang, Nicos A. Nicola, Evdokia Dimitriadis Leukemia Inhibitory Factor (LIF) Inhibition during Mid-Gestation Impairs Trophoblast Invasion and Spiral Artery Remodelling during Pregnancy in Mice PLOS ONE 2015-10-19 [PMID: 26479247]
• Amy Winship, Jeanne Correia, Tara Krishnan, Ellen Menkhorst, Carly Cuman, Jian-Guo Zhang et al. Blocking Endogenous Leukemia Inhibitory Factor During Placental Development in Mice Leads to Abnormal Placentation and Pregnancy Loss Scientific Reports 2015-08-14 [PMID: 26272398]
• Xiao Y, Sun X, Yang X, Zhang J, Xue Q, Cai B, Zhou Y Leukemia inhibitory factor is dysregulated in the endometrium and uterine flushing fluid of patients with adenomyosis during implantation window. Fertil. Steril., 2009-04-09;94(1):85-9. 2009-04-09 [PMID: 19361790] (Immunohistochemistry-Paraffin, Human)
• Aghajanova L, Altmae S, Bjuresten K, Hovatta O, Landgren BM, Stavreus-Evers A Disturbances in the LIF pathway in the endometrium among women with unexplained infertility. Fertil. Steril., 2008-08-05;91(6):2602-10. 2008-08-05 [PMID: 18684446] (IHC-P, Human)
• Meng CX, Andersson KL, Bentin-Ley U, Gemzell-Danielsson K, Lalitkumar PG Effect of levonorgestrel and mifepristone on endometrial receptivity markers in a three-dimensional human endometrial cell culture model. Fertil. Steril., 2008-01-18;91(1):256-64. 2008-01-18 [PMID: 18206148] (ICC, Human)
• Kamohara H, Ogawa M, Ishiko T, Sakamoto K, Baba H Leukemia inhibitory factor functions as a growth factor in pancreas carcinoma cells: Involvement of regulation of LIF and its receptor expression. Int. J. Oncol., 2007-04-01;30(4):977-83. 2007-04-01 [PMID: 17332938] (Neutralization, Human)
• Aghajanova L, Skottman H, Stromberg AM, Inzunza J, Lahesmaa R, Hovatta O Expression of leukemia inhibitory factor and its receptors is increased during differentiation of human embryonic stem cells. Fertil. Steril., 2006-09-01;86(4):1193-209. 2006-09-01 [PMID: 16949591] (ICC, Human)
• He W, Gong K, Smith DK, Ip NY The N-terminal cytokine binding domain of LIFR is required for CNTF binding and signaling. FEBS Lett., 2005-08-15;579(20):4317-23. 2005-08-15 [PMID: 16051226] (Western Blot, Human)
• Andersson By U, Tani E, Andersson U Tumor necrosis factor, interleukin 11, and leukemia inhibitory factor produced by Langerhans cells in Langerhans cell histiocytosis. J. Pediatr. Hematol. Oncol., 2004-11-01;26(11):706-11. 2004-11-01 [PMID: 15543003] (ICC, Human)
• Sengupta J, Dhawan L, Ghosh D Immunohistochemical localization of leukemia inhibitory factor, interleukins 1 and 6 at the primary implantation site in the rhesus monkey. Cytokine, 2003-12-21;24(6):277-85. 2003-12-21 [PMID: 14609569] (IHC-P, Primate - Macaca mulatta (Rhesus Macaque))
• Ben-Shlomo A, Miklovsky I, Ren SG, Yong WH, Heaney AP, Culler MD, Melmed S Leukemia inhibitory factor regulates prolactin secretion in prolactinoma and lactotroph cells. J. Clin. Endocrinol. Metab., 2003-02-01;88(2):858-63. 2003-02-01 [PMID: 12574225] (IHC-P, Human)

Bioinformatics

• Gene Symbol: LIF
• Uniprot:
  • P15018()